Cardiff goes south again
The latest onvansertib data, and an abrupt CEO departure, spook investors.
Novartis perseveres with pelabresib
A new phase 3, Manifest-3, will start in April to support US filing.
Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
Pfizer trims its pan-KRAS efforts
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
Black Diamond advances in brain cancer
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
RAS buzz lifts Erasca
But the company still has a lot to prove with ERAS-0015.
BridgeBio Oncology shows early promise
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
Syndax switches first-line plans
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
